SlideShare ist ein Scribd-Unternehmen logo
1 von 18
Anticancer
Alkylating agents
Dr. S. Parasuraman
Faculty of Pharmacy, AIMST.
Alkylating agents
Nitrogen mustards

Ethylenimine
Alkyl sulfonate
Nitrosoureas
Triazine
Methylhyderazine

Mechlorethamine
Cyclophosphamide
Ifosfamide
Chlorambucil
Melphalan
Thio-TEPA
Busulfan
Carmustine
Lomustine
Dacarbazine
Temozolomide
Procarbazine
Alkylating agents
• Alkylating agents produce highly reactive carbonium ion
intermediates or related transition complex which
transfer alkyl group to cellular macromolecules by
covalent bonds.

• Alkylating agents cross link with carboxyl, hydroxyl,
amino,

sulfhydryl

and

phosphate

groups

of

biomacromolecules results abnormal base paring/
scission of DNA Stand.
Alkylating agents
MOA & SAR:

The chemotherapeutic
and cytotoxic effects
are directly related to
the alkylation of DNA.
The 7th nitrogen atom
of guanine is suitable
for
formation
of
covalent bond with
bifunctional alkylating
agent.
Pharmacological actions
• Cytotoxic actions:
– Interfere with DNA integrity and functions to induce cell

death in rapidly proliferating tissues.
– Lethality of DNA alkylation depends on the recognition of
the adduct, the creation of DNA stand breaks by repair

enzymes.
– In nondividing cells, DNA damage activation depends on the
presence of p53 gene. Malignant cells with mutant/ absent

p53 gene fail to suspend cell-cycle progression (don’t cause
apoptosis) and exhibit resistance to alkylating agents.
Toxicities of alkylating agents
• Bone marrow toxicity
– Causes dose-dependent toxicity to bone marrow elements
– Myelosuppression
– Suppression of cellular and humoral immunity

• Mucosal toxicity
– Highly toxic to mucosal cells and intestinal mucosa

• Neurotoxicity
– Nausea, vomiting (after I.V administration)
– Ifosfamide is the most neurotoxic agent in this class (alter
mental status, coma, generalized seizures and cerebellar ataxia)

• Other: Leukemogensis, male and female reproductive
system toxicity.
• Mechlorethamine
–
–
–
–
–

First nitrogen mustard; most reactive
Slow I.V. injection may cause sloughing
Used for Hodgkin and non-Hodgkin lymphomas
Largely replaced by cyclophosphamide and melphalan.
Dose: 0.1 mg/kg i.v. daily X 4 days (courses may be
repeated at suitable intervals)
– It is also used topically for treatment of cutaneous T-cell
lymphoma
– Toxicity: Block reproductive functions, produce menstrual
irregularities or premature ovarian failure in women and
oligospermia in men. First trimester of pregnancy and later
stage of pregnancy it should not be used.
• Cyclophosphosphamide
– Inactive as such
– Transformed to active metabolites in liver:
(aldophosphamide, phosphoramide mustard)
– Chloramphenicol retards the metabolism of
cyclophosphamide.
– It is well absorbed orally, activated by CYP2B.
– Cyclophosphamide is potent immunosuppressive agent, it
has been used to prevent organ rejection after
transplantation.
– Dose: 2-3 mg/kg/ day oral; 10-15 mg/kg i.v.
• Ifosfamide
– Analog of cyclophosphamide has a longer dose-dependent
t1/2 and it also activated by hydroxylation in the liver.
– Used in bronchogenic, breast, testicular, bladder, head and
neck carcinomas, oeseogenic sarcoma and some lymphomas.
– Approved for germ cell testicular cancer
– Produce dose limiting toxicity – haemorrhagic cystitis. Sever
urinary tract and CNS toxicity
– Toxicity can be reduced by administering mesna (-SH
compound). mesna inactivates the vasicotoxic metabolites of
ifosfamide and cyclophosphamide.
– Ifosfamide causes less alopecia and is less emetogenic than
cyclophosphamide.
– Dose: 0.1 g inj.
• Chlorambucil
– Slow acting alkylating agent
– Active against lymphoid, myeloid tissue cancers
– It is the drug of choice for the long-term maintenance
therapy for chronic lymphatic leukaemia, non-Hodgkin
lymphoma and few solid tumours.
– It has immunosuppressant property
– Dose: 4-10 mg daily for 3-6 weeks, then 2 mg/kg daily for
maintenance
• Melphalan
– The pharmacological and cytotoxic properties of
melphalan is similar to mechlorethamine. The drug is not a
vesicant
– Effective in multiple myeloma and advanced ovarian
cancer
– Toxicity: Bone marrow toxicity
– Dose: 10 mg daily for 7 days or 6 mg/ day for 2-3 weeks-----------4 weeks gap--------- 2 to 4 mg/day for maintenance
orally.
• Thio-TEPA
–
–
–
–

It is an ethylenimine
Highly toxic
Used in ovarian and bladder cancer
Dose: 0.3-0.4 mg/kg i.v. at 1-4 weeks intervels
• Busulfan
– Highly specific for myeloid elements and granulocyte
– Toxicity: hyperuricaemia is common; pulmonary fibrosis
and skin pigmentation are specific adverse effects.
– Drug of choice for chronic myeloid leukaemia
– Dose: 2-6 mg/ day, orally
• Nitrosoureas
– It is lipid soluble alkylating agents with a wide range of
antitumour activity.
– Cross BBM
– Effective in meningeal leukaemias and brain cancer
– Toxicity: Nausea, vomiting are common; CNS toxicity, bone
marrow depression (delayed effect; will take 6 weeks to
develop), visceral fibrosis and renal damage can occur
– Dose: 100-130 mg/m2 BSA single oral dose every 6 weeks.
• Dacarbazine (DTIC)
– After activation in liver, the active metabolite methylate
the DNA and interfere with its function.
– Used for malignant melanoma, Hodgkin’s disease
– Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy
and myelosuppression
– Dose: 3.5 mg/kg/day i.v. for 10 days, repeated after 4
weeks
• Temozolamide
– Orally active triazine methylating agent is the drug of
choice for glioma and other malignant brain tumour.
– Also used for melanoma
– Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy
and myelosuppression
– Dose: 100- 200 mg/day
• Procarbazine
– It is not classical alkylating agent, but has similar
properties.
– After metabolizing, procarbazine methylates and
depolymerizes DNA and causing chromosomal damage
and inhibit nucleic acid synthesis.
– Procarbazine is component of MOPP regimen for Hodgkin’s
and related lymphomas and alternative drug for brain
tumours.
– It is a week MAO inhibitor, produce sedation and other
CNS effects.
– Interact with food, drugs and alcohol. With alcohol,
procarbazine causes hot flushing and disulfiram-like
reaction.
– Toxicity: Vomiting, leucopenia, thrombocytopenia
– Dose: 100 mg/m2/ dayfor 14 days in 28 days cycle.
Thank you

Weitere ähnliche Inhalte

Was ist angesagt?

2. alkylating & anti-metabolite drugs
2. alkylating  &  anti-metabolite drugs2. alkylating  &  anti-metabolite drugs
2. alkylating & anti-metabolite drugsHarshikaPatel6
 
Medicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsMedicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsDHARMENDRA BARIA
 
Antineoplastic agents
Antineoplastic agentsAntineoplastic agents
Antineoplastic agentsRobin Gulati
 
Introduction to chemotherapy of cancer
Introduction to chemotherapy of cancerIntroduction to chemotherapy of cancer
Introduction to chemotherapy of cancerSubramani Parasuraman
 
Antileprotic drugs
Antileprotic drugsAntileprotic drugs
Antileprotic drugsDr. Pramod B
 
Alkylating Agents & Anti-metabolites Chemotherapy
Alkylating Agents & Anti-metabolites ChemotherapyAlkylating Agents & Anti-metabolites Chemotherapy
Alkylating Agents & Anti-metabolites ChemotherapyAaditya Prakash
 
cancer chemotherapy
cancer chemotherapycancer chemotherapy
cancer chemotherapyNaser Tadvi
 
Medicinal chemistry- antimalerial agents
Medicinal chemistry- antimalerial agentsMedicinal chemistry- antimalerial agents
Medicinal chemistry- antimalerial agentsDHARMENDRA BARIA
 
Chemotherapy of malignancy
Chemotherapy of malignancyChemotherapy of malignancy
Chemotherapy of malignancyAtul Prajapati
 
Vinca Alkaloids as Anticancer Agents (Looking back and peering ahead)
Vinca Alkaloids as Anticancer Agents (Looking back and peering ahead)Vinca Alkaloids as Anticancer Agents (Looking back and peering ahead)
Vinca Alkaloids as Anticancer Agents (Looking back and peering ahead)Mohammad Abrar Khan
 
Medicinal chemistry of Anti viral agents
 Medicinal chemistry of Anti viral agents  Medicinal chemistry of Anti viral agents
Medicinal chemistry of Anti viral agents Soujanya Pharm.D
 
Class anticancer drugs
Class anticancer drugsClass anticancer drugs
Class anticancer drugsRaghu Prasada
 
Clinical Symptoms and Management of Morphine ,Organophosphorus and Mercury ...
Clinical Symptoms and  Management of Morphine ,Organophosphorus and  Mercury ...Clinical Symptoms and  Management of Morphine ,Organophosphorus and  Mercury ...
Clinical Symptoms and Management of Morphine ,Organophosphorus and Mercury ...Drx Piyush Lodhi
 
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.Dr. Ravi Sankar
 
Pharmacology - Immunosupressants
Pharmacology - ImmunosupressantsPharmacology - Immunosupressants
Pharmacology - ImmunosupressantsAreej Abu Hanieh
 

Was ist angesagt? (20)

2. alkylating & anti-metabolite drugs
2. alkylating  &  anti-metabolite drugs2. alkylating  &  anti-metabolite drugs
2. alkylating & anti-metabolite drugs
 
Medicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsMedicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agents
 
Antineoplastic agents
Antineoplastic agentsAntineoplastic agents
Antineoplastic agents
 
Introduction to chemotherapy of cancer
Introduction to chemotherapy of cancerIntroduction to chemotherapy of cancer
Introduction to chemotherapy of cancer
 
Antileprotic drugs
Antileprotic drugsAntileprotic drugs
Antileprotic drugs
 
Basic principles of chemotherapy
Basic principles of chemotherapyBasic principles of chemotherapy
Basic principles of chemotherapy
 
Alkylating Agents & Anti-metabolites Chemotherapy
Alkylating Agents & Anti-metabolites ChemotherapyAlkylating Agents & Anti-metabolites Chemotherapy
Alkylating Agents & Anti-metabolites Chemotherapy
 
cancer chemotherapy
cancer chemotherapycancer chemotherapy
cancer chemotherapy
 
Anti Cancer Drugs
Anti  Cancer DrugsAnti  Cancer Drugs
Anti Cancer Drugs
 
Medicinal chemistry- antimalerial agents
Medicinal chemistry- antimalerial agentsMedicinal chemistry- antimalerial agents
Medicinal chemistry- antimalerial agents
 
Chemotherapy of malignancy
Chemotherapy of malignancyChemotherapy of malignancy
Chemotherapy of malignancy
 
Vinca Alkaloids as Anticancer Agents (Looking back and peering ahead)
Vinca Alkaloids as Anticancer Agents (Looking back and peering ahead)Vinca Alkaloids as Anticancer Agents (Looking back and peering ahead)
Vinca Alkaloids as Anticancer Agents (Looking back and peering ahead)
 
10.ANTICANCER DRUGS
10.ANTICANCER DRUGS10.ANTICANCER DRUGS
10.ANTICANCER DRUGS
 
Medicinal chemistry of Anti viral agents
 Medicinal chemistry of Anti viral agents  Medicinal chemistry of Anti viral agents
Medicinal chemistry of Anti viral agents
 
Antihistamines
AntihistaminesAntihistamines
Antihistamines
 
Class anticancer drugs
Class anticancer drugsClass anticancer drugs
Class anticancer drugs
 
Anti Amoebic Drugs
Anti Amoebic DrugsAnti Amoebic Drugs
Anti Amoebic Drugs
 
Clinical Symptoms and Management of Morphine ,Organophosphorus and Mercury ...
Clinical Symptoms and  Management of Morphine ,Organophosphorus and  Mercury ...Clinical Symptoms and  Management of Morphine ,Organophosphorus and  Mercury ...
Clinical Symptoms and Management of Morphine ,Organophosphorus and Mercury ...
 
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
 
Pharmacology - Immunosupressants
Pharmacology - ImmunosupressantsPharmacology - Immunosupressants
Pharmacology - Immunosupressants
 

Ähnlich wie Anticancer drugs 2 alkylating agents

ALKYLATING AGENT. antineoplastic agentspptx
ALKYLATING AGENT. antineoplastic agentspptxALKYLATING AGENT. antineoplastic agentspptx
ALKYLATING AGENT. antineoplastic agentspptxDevakiKondaveeti2
 
ALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdfALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdfrazee khwaja
 
Anticancer drugs1
Anticancer drugs1Anticancer drugs1
Anticancer drugs1sarekat7
 
Alkylating agents -Medicinal Chemistry
Alkylating agents -Medicinal Chemistry Alkylating agents -Medicinal Chemistry
Alkylating agents -Medicinal Chemistry NarminHamaaminHussen
 
Chemotherapeutic agents
Chemotherapeutic agents Chemotherapeutic agents
Chemotherapeutic agents prachiupadhyay8
 
Classification of anti cancer drugs
Classification of anti cancer drugs Classification of anti cancer drugs
Classification of anti cancer drugs pgclubrcc
 
Chemotherapeutic agents in ENT
Chemotherapeutic agents in ENTChemotherapeutic agents in ENT
Chemotherapeutic agents in ENTAVINAV GUPTA
 
Chemotherapy in Breast Cancer
Chemotherapy in Breast CancerChemotherapy in Breast Cancer
Chemotherapy in Breast CancerDr. Shaurya Mehra
 
Chemotherapy drugs in gynecological oncology
Chemotherapy drugs in gynecological oncologyChemotherapy drugs in gynecological oncology
Chemotherapy drugs in gynecological oncologySravanthi Nuthalapati
 
Neoplasm and Antineoplastic Agents
Neoplasm and Antineoplastic AgentsNeoplasm and Antineoplastic Agents
Neoplasm and Antineoplastic Agentspankaj patel
 
Anticancer compounds.ppt
Anticancer compounds.pptAnticancer compounds.ppt
Anticancer compounds.pptPravinKhatale2
 
Chapter 20 alkylating agent extra
Chapter 20  alkylating agent extraChapter 20  alkylating agent extra
Chapter 20 alkylating agent extraNilesh Kucha
 
CHEMOTHERAPY IN ENT
CHEMOTHERAPY IN ENTCHEMOTHERAPY IN ENT
CHEMOTHERAPY IN ENTRazal M
 

Ähnlich wie Anticancer drugs 2 alkylating agents (20)

ALKYLATING AGENT. antineoplastic agentspptx
ALKYLATING AGENT. antineoplastic agentspptxALKYLATING AGENT. antineoplastic agentspptx
ALKYLATING AGENT. antineoplastic agentspptx
 
ALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdfALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdf
 
Anticancer drugs1
Anticancer drugs1Anticancer drugs1
Anticancer drugs1
 
Alkylating agents -Medicinal Chemistry
Alkylating agents -Medicinal Chemistry Alkylating agents -Medicinal Chemistry
Alkylating agents -Medicinal Chemistry
 
Chemotherapeutic agents
Chemotherapeutic agents Chemotherapeutic agents
Chemotherapeutic agents
 
Classification of anti cancer drugs
Classification of anti cancer drugs Classification of anti cancer drugs
Classification of anti cancer drugs
 
Chemotherapeutic agents in ENT
Chemotherapeutic agents in ENTChemotherapeutic agents in ENT
Chemotherapeutic agents in ENT
 
Antituberculosis drugs
Antituberculosis drugsAntituberculosis drugs
Antituberculosis drugs
 
Chemotherapy in Breast Cancer
Chemotherapy in Breast CancerChemotherapy in Breast Cancer
Chemotherapy in Breast Cancer
 
Anti tuberculin drugs [autosaved]
Anti tuberculin drugs [autosaved]Anti tuberculin drugs [autosaved]
Anti tuberculin drugs [autosaved]
 
Anticancer drugs
Anticancer drugsAnticancer drugs
Anticancer drugs
 
Anticancer drugs - drdhriti
Anticancer drugs - drdhritiAnticancer drugs - drdhriti
Anticancer drugs - drdhriti
 
Chemotherapy drugs in gynecological oncology
Chemotherapy drugs in gynecological oncologyChemotherapy drugs in gynecological oncology
Chemotherapy drugs in gynecological oncology
 
Neoplasm and Antineoplastic Agents
Neoplasm and Antineoplastic AgentsNeoplasm and Antineoplastic Agents
Neoplasm and Antineoplastic Agents
 
Dapsone, colchicine
Dapsone, colchicineDapsone, colchicine
Dapsone, colchicine
 
Antituberculosis drugs converted
Antituberculosis drugs convertedAntituberculosis drugs converted
Antituberculosis drugs converted
 
Anticancer compounds.ppt
Anticancer compounds.pptAnticancer compounds.ppt
Anticancer compounds.ppt
 
Chapter 20 alkylating agent extra
Chapter 20  alkylating agent extraChapter 20  alkylating agent extra
Chapter 20 alkylating agent extra
 
CHEMOTHERAPY IN ENT
CHEMOTHERAPY IN ENTCHEMOTHERAPY IN ENT
CHEMOTHERAPY IN ENT
 
chemotheraphy in ent.pdf
chemotheraphy in ent.pdfchemotheraphy in ent.pdf
chemotheraphy in ent.pdf
 

Mehr von Subramani Parasuraman

Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)Subramani Parasuraman
 
Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)Subramani Parasuraman
 
Research with animals and animal models.pptx
Research with animals and animal models.pptxResearch with animals and animal models.pptx
Research with animals and animal models.pptxSubramani Parasuraman
 
Cerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptxCerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptxSubramani Parasuraman
 
Drugs used in haematological disorders
Drugs used in haematological disordersDrugs used in haematological disorders
Drugs used in haematological disordersSubramani Parasuraman
 

Mehr von Subramani Parasuraman (20)

Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)
 
Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)
 
Research with animals and animal models.pptx
Research with animals and animal models.pptxResearch with animals and animal models.pptx
Research with animals and animal models.pptx
 
Nicotine and Tobacco
Nicotine and TobaccoNicotine and Tobacco
Nicotine and Tobacco
 
Statistical software.pptx
Statistical software.pptxStatistical software.pptx
Statistical software.pptx
 
Cerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptxCerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptx
 
Drugs Used in Renal Alteration
Drugs Used in Renal AlterationDrugs Used in Renal Alteration
Drugs Used in Renal Alteration
 
Drugs Used in Endocrine Alteration
Drugs Used in Endocrine AlterationDrugs Used in Endocrine Alteration
Drugs Used in Endocrine Alteration
 
Antidiabetic drugs
Antidiabetic drugsAntidiabetic drugs
Antidiabetic drugs
 
Pancreatic Hormones
Pancreatic HormonesPancreatic Hormones
Pancreatic Hormones
 
Terrestrial laboratory animals
Terrestrial laboratory animalsTerrestrial laboratory animals
Terrestrial laboratory animals
 
Drugs used in haematological disorders
Drugs used in haematological disordersDrugs used in haematological disorders
Drugs used in haematological disorders
 
Laboratory animals
Laboratory animalsLaboratory animals
Laboratory animals
 
Immunomodulators-1.pptx
Immunomodulators-1.pptxImmunomodulators-1.pptx
Immunomodulators-1.pptx
 
Immunomodulators - 3.pptx
Immunomodulators - 3.pptxImmunomodulators - 3.pptx
Immunomodulators - 3.pptx
 
Immunomodulators - 2.pptx
Immunomodulators - 2.pptxImmunomodulators - 2.pptx
Immunomodulators - 2.pptx
 
Acetylcholine bioassay
 Acetylcholine bioassay Acetylcholine bioassay
Acetylcholine bioassay
 
Oxytocin bioassay
Oxytocin bioassayOxytocin bioassay
Oxytocin bioassay
 
Type of bioassays
Type of bioassaysType of bioassays
Type of bioassays
 
Principles of bioassay
Principles of bioassayPrinciples of bioassay
Principles of bioassay
 

Kürzlich hochgeladen

CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxGaneshChakor2
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docxPoojaSen20
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Celine George
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptxContemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptxRoyAbrique
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3JemimahLaneBuaron
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991RKavithamani
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAssociation for Project Management
 
Micromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of PowdersMicromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of PowdersChitralekhaTherkar
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentInMediaRes1
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityGeoBlogs
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxmanuelaromero2013
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...EduSkills OECD
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxOH TEIK BIN
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppCeline George
 

Kürzlich hochgeladen (20)

CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptx
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docx
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptxContemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across Sectors
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
Staff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSDStaff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSD
 
Micromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of PowdersMicromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of Powders
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media Component
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptx
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptx
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website App
 

Anticancer drugs 2 alkylating agents

  • 1. Anticancer Alkylating agents Dr. S. Parasuraman Faculty of Pharmacy, AIMST.
  • 2. Alkylating agents Nitrogen mustards Ethylenimine Alkyl sulfonate Nitrosoureas Triazine Methylhyderazine Mechlorethamine Cyclophosphamide Ifosfamide Chlorambucil Melphalan Thio-TEPA Busulfan Carmustine Lomustine Dacarbazine Temozolomide Procarbazine
  • 3. Alkylating agents • Alkylating agents produce highly reactive carbonium ion intermediates or related transition complex which transfer alkyl group to cellular macromolecules by covalent bonds. • Alkylating agents cross link with carboxyl, hydroxyl, amino, sulfhydryl and phosphate groups of biomacromolecules results abnormal base paring/ scission of DNA Stand.
  • 4. Alkylating agents MOA & SAR: The chemotherapeutic and cytotoxic effects are directly related to the alkylation of DNA. The 7th nitrogen atom of guanine is suitable for formation of covalent bond with bifunctional alkylating agent.
  • 5. Pharmacological actions • Cytotoxic actions: – Interfere with DNA integrity and functions to induce cell death in rapidly proliferating tissues. – Lethality of DNA alkylation depends on the recognition of the adduct, the creation of DNA stand breaks by repair enzymes. – In nondividing cells, DNA damage activation depends on the presence of p53 gene. Malignant cells with mutant/ absent p53 gene fail to suspend cell-cycle progression (don’t cause apoptosis) and exhibit resistance to alkylating agents.
  • 6. Toxicities of alkylating agents • Bone marrow toxicity – Causes dose-dependent toxicity to bone marrow elements – Myelosuppression – Suppression of cellular and humoral immunity • Mucosal toxicity – Highly toxic to mucosal cells and intestinal mucosa • Neurotoxicity – Nausea, vomiting (after I.V administration) – Ifosfamide is the most neurotoxic agent in this class (alter mental status, coma, generalized seizures and cerebellar ataxia) • Other: Leukemogensis, male and female reproductive system toxicity.
  • 7. • Mechlorethamine – – – – – First nitrogen mustard; most reactive Slow I.V. injection may cause sloughing Used for Hodgkin and non-Hodgkin lymphomas Largely replaced by cyclophosphamide and melphalan. Dose: 0.1 mg/kg i.v. daily X 4 days (courses may be repeated at suitable intervals) – It is also used topically for treatment of cutaneous T-cell lymphoma – Toxicity: Block reproductive functions, produce menstrual irregularities or premature ovarian failure in women and oligospermia in men. First trimester of pregnancy and later stage of pregnancy it should not be used.
  • 8. • Cyclophosphosphamide – Inactive as such – Transformed to active metabolites in liver: (aldophosphamide, phosphoramide mustard) – Chloramphenicol retards the metabolism of cyclophosphamide. – It is well absorbed orally, activated by CYP2B. – Cyclophosphamide is potent immunosuppressive agent, it has been used to prevent organ rejection after transplantation. – Dose: 2-3 mg/kg/ day oral; 10-15 mg/kg i.v.
  • 9. • Ifosfamide – Analog of cyclophosphamide has a longer dose-dependent t1/2 and it also activated by hydroxylation in the liver. – Used in bronchogenic, breast, testicular, bladder, head and neck carcinomas, oeseogenic sarcoma and some lymphomas. – Approved for germ cell testicular cancer – Produce dose limiting toxicity – haemorrhagic cystitis. Sever urinary tract and CNS toxicity – Toxicity can be reduced by administering mesna (-SH compound). mesna inactivates the vasicotoxic metabolites of ifosfamide and cyclophosphamide. – Ifosfamide causes less alopecia and is less emetogenic than cyclophosphamide. – Dose: 0.1 g inj.
  • 10. • Chlorambucil – Slow acting alkylating agent – Active against lymphoid, myeloid tissue cancers – It is the drug of choice for the long-term maintenance therapy for chronic lymphatic leukaemia, non-Hodgkin lymphoma and few solid tumours. – It has immunosuppressant property – Dose: 4-10 mg daily for 3-6 weeks, then 2 mg/kg daily for maintenance
  • 11. • Melphalan – The pharmacological and cytotoxic properties of melphalan is similar to mechlorethamine. The drug is not a vesicant – Effective in multiple myeloma and advanced ovarian cancer – Toxicity: Bone marrow toxicity – Dose: 10 mg daily for 7 days or 6 mg/ day for 2-3 weeks-----------4 weeks gap--------- 2 to 4 mg/day for maintenance orally.
  • 12. • Thio-TEPA – – – – It is an ethylenimine Highly toxic Used in ovarian and bladder cancer Dose: 0.3-0.4 mg/kg i.v. at 1-4 weeks intervels
  • 13. • Busulfan – Highly specific for myeloid elements and granulocyte – Toxicity: hyperuricaemia is common; pulmonary fibrosis and skin pigmentation are specific adverse effects. – Drug of choice for chronic myeloid leukaemia – Dose: 2-6 mg/ day, orally
  • 14. • Nitrosoureas – It is lipid soluble alkylating agents with a wide range of antitumour activity. – Cross BBM – Effective in meningeal leukaemias and brain cancer – Toxicity: Nausea, vomiting are common; CNS toxicity, bone marrow depression (delayed effect; will take 6 weeks to develop), visceral fibrosis and renal damage can occur – Dose: 100-130 mg/m2 BSA single oral dose every 6 weeks.
  • 15. • Dacarbazine (DTIC) – After activation in liver, the active metabolite methylate the DNA and interfere with its function. – Used for malignant melanoma, Hodgkin’s disease – Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy and myelosuppression – Dose: 3.5 mg/kg/day i.v. for 10 days, repeated after 4 weeks
  • 16. • Temozolamide – Orally active triazine methylating agent is the drug of choice for glioma and other malignant brain tumour. – Also used for melanoma – Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy and myelosuppression – Dose: 100- 200 mg/day
  • 17. • Procarbazine – It is not classical alkylating agent, but has similar properties. – After metabolizing, procarbazine methylates and depolymerizes DNA and causing chromosomal damage and inhibit nucleic acid synthesis. – Procarbazine is component of MOPP regimen for Hodgkin’s and related lymphomas and alternative drug for brain tumours. – It is a week MAO inhibitor, produce sedation and other CNS effects. – Interact with food, drugs and alcohol. With alcohol, procarbazine causes hot flushing and disulfiram-like reaction. – Toxicity: Vomiting, leucopenia, thrombocytopenia – Dose: 100 mg/m2/ dayfor 14 days in 28 days cycle.

Hinweis der Redaktion

  1. MOPP is a combination chemotherapy regimen used to treat Hodgkin's disease. The acronym is derived from the component drugs of the regimen:Mustargen (also known as mechlorethamine, mustine, nitrogen mustard, or MSD)Oncovin (also known as Vincristine or VCR)Procarbazine (also known as Matulane or Natulan) Prednisone (also known as Deltasone or Orasone)